

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Potential Dose-response Effect of Postprocedural Elevated Cardiac Troponin Level on Adverse Clinical Outcomes Following Noncardiac Surgery: A Systematic Review Protocol of Prospective Studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046223
Article Type:	Protocol
Date Submitted by the Author:	23-Oct-2020
Complete List of Authors:	An, Tao; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Heart failure center Tian, Yue; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Echocardiography Guo, Jingfei; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology Kang, Wenying; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology Tian, Tao; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Zhou, Chenghui; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology
Keywords:	Adult anaesthesia < ANAESTHETICS, Adult intensive & critical care < ANAESTHETICS, Anaesthesia in cardiology < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Dose-response Effect of Postprocedural Elevated Cardiac Troponin Level on Adverse Clinical Outcomes Following Adult Noncardiac Surgery: A Systematic Review Protocol of Prospective Studies

Tao An¹, M.D, Ph.D; Yue Tian², M.D; Jingfei Guo¹, M.D; Wenyang Kang, M.D; Tao Tian^{*3}, M.D, Ph.D ; Chenghui Zhou^{*4}, M.D, Ph.D,

¹State Key Laboratory of Cardiovascular Disease, Heart Failure Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

²Department of Echocardiography, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, China

³Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing, China.

⁴Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

***Address for Correspondence:** Tao Tian and Chenghui Zhou;

No. 167 Beilishi Road, 100037 Xicheng District, Beijing, China

Tel: 86-10-88398082, Fax: 86-10-88398082

E-mail: tiantaophd@163.com (Tian T); chenghuizhou@yahoo.com (Zhou Ch) .

Word Count: 3053 words.

ABSTRACT

Introduction Myocardial injury after noncardiac surgery (MINS) has been recognized as one important complication in association with short-term and long-term morbidity and mortality. The potential dose response effect of postprocedural cardiac troponin (cTn) levels on adverse clinical outcomes has not been studied. Hence, we will conduct a comprehensive dose-response meta-analysis based on the all related prospective studies to quantitatively evaluate the association between the postoperative elevated cTn levels and short-/long-term adverse clinical outcomes following noncardiac surgery.

Methods We will search PubMed, EMBase, Cochrane Library, and ISI Knowledge via Web of Science database (from inception until Oct, 2020) to identify all prospective cohort studies using the related keywords. The primary outcome will be all-cause mortality. The second outcomes will include cardiovascular mortality and major adverse cardiovascular event (MACE). Univariate or multivariate meta-regression and subgroup analyses will be conducted for the comparison between elevated versus non-elevated categories of postoperative cTn level. Sensitivity analyses were used to assess the robustness of our results by removing each included study at one time to obtain and evaluate the remaining overall estimates of all-cause mortality or MACE. To conduct a dose-response meta-analysis for the potential linear or restricted cubic spline regression relationship between postoperative elevated cTn levels and all-cause mortality or MACE, studies with three or more categories will be included.

Ethics and dissemination Ethical approval is waived for the systematic review protocol according to the Institutional Review Board /Independent Ethics Committee of Fuwai Hospital. This meta-analysis will be disseminated through a peer-reviewed journal for publication and conference presentations.

Keywords: myocardial injury, noncardiac surgery, postoperative cardiac troponin,

1
2
3
4 dose-response
5

6 **PROSPERO registration number** CRD42020173175.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

1. This meta-analysis will be the first one to explore the potential linear or nonlinear dose-response relationship between postoperative cTn level and adverse clinical outcomes in adult non-cardiac surgery.
2. This meta-analysis will be the first one focusing the prognostic significance of subclinical or tiny myocardial injury below URL.
3. This meta-analysis will include the largest study population with only prospective enrollment.
4. The baseline cTn level is not a regular test for patients undergoing noncardiac surgery resulting insufficient data.
5. This work could not rule out the potential influence of different detection kit and method for the cTn level in the included studies

Introduction

Myocardial injury after noncardiac surgery (MINS) has been recognized as one important complication in association with short-term and long-term morbidity and mortality¹. Some studies have showed that the incidence of MINS is common as many as 30~45% based on postoperative high sensitive cardiac troponin(cTn) level²⁻⁴. The major proposed mechanism of MINS is imbalance of myocardial oxygen supply-demand including perioperative hypotension⁵, hypoxia⁶, anemia⁷, previous coronary artery disease⁸, and coronary thrombosis⁹. Postoperative cTn measurement is recommended in high-risk patients undergoing noncardiac surgery. According to the latest fourth Universal Definition of Myocardial Infarction (UDMI) in 2018⁶, the cutoff value for regularly diagnosing MINS is the 99th percentile upper reference limit (URL) of postoperative cTn level. However, increase in the prognostic effect of cTn still requires the newly-onset ischemia-related evidence of myocardium including electrocardiogram, echocardiography, coronary computed tomography (CT), or coronary angiography⁶. However, these cardiac-specific examinations are not regularly used in patients undergoing noncardiac surgery, and may increase a large amount of cost during hospitalization.

Given the limited high-quality evidence and controversial findings from available studies concerning the long-term prognostic significance following noncardiac surgery, whether there is an optimal cutoff value for postoperative cTn level to diagnose MINS with improved prognostic significance remains unknown¹⁰⁻¹⁶. Moreover, quantitative analysis for the myocardial injury below the recommended URL has not been systematically studied¹⁷. Hence, we will conduct a comprehensive dose-response meta-analysis based on the all related prospective studies to quantitatively evaluate the association between the postoperative elevated cTn levels and short-/long-term adverse clinical outcomes following noncardiac surgery.

Objectives

The purpose of this systematic review and meta-analysis is to explore the potential dose-response relationship between postoperative elevated cTn levels and adverse clinical outcomes after adult noncardiac surgery.

METHODS AND ANALYSIS

Search Strategy

We will report this meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guideline¹⁸. We will search PubMed, EMBase, Cochrane Library, and ISI Knowledge via Web of Science database (from inception until Oct, 2020), and the reference lists of the retrieved articles. The related search keywords are listed in Table 1. This meta-analysis has been registered in the PROSPERO with registration ID CRD42020173175. The searching process is shown in Figure 1.

Type of Participants

We will include adult patients undergoing noncardiac surgery as study participants.

Type of Studies

We will include prospective cohort studies that have reported the associations of the postoperative cardiac troponin levels with the incidence of major adverse clinical outcomes. The publication language will be limited as English. The studies unable to extract odds ratio(OR) or hazard ration(HR) and the corresponding 95% confidence intervals (CI) will be excluded.

Type of Outcomes

The primary outcome will be all-cause mortality. The second outcomes will include cardiovascular mortality and major adverse cardiovascular event (MACE).

1
2
3
4 MACE is a combined endpoint including at least three of the following events: death,
5 cardiovascular death, any cause for coronary revascularization, unstable angina,
6 myocardial infarction, congestive heart failure, major adverse arrhythmias requiring
7 treatment, cardiac arrest, pulmonary embolism, or stroke. The follow-up duration will
8 be divided into three time periods: ‘short term (1-3 months)’ , ‘medium term
9 (3~12 months)’ , and ‘long term (≥ 1 year)’ . Both primary outcome and second
10 outcome will be included in the analysis of potential dose-response effect.
11
12
13
14
15
16
17
18
19

20 **Data Extraction**

21
22 Data will be extracted by two independent authors (T. An and T. Yue).
23
24 Discrepancies will be resolved by group discussion. The extracted data included study
25 design (author, publication year, country, sample size, percentage of positive cTn
26 levels), patient characteristics (mean age, male proportion, diabetes proportion,
27 hypertension proportion, hyperlipidemia proportion, smoking proportion, coronary
28 artery disease[CAD] proportion, previous myocardial infarction, chronic heart failure,
29 atrial fibrillation, history of valvular heart disease, history of peripheral vascular
30 disease, history of stroke or transient ischemic accident, kidney dysfunction, history
31 of lung disease, history of liver disease, elective surgery proportion, vascular surgery
32 proportion, general anesthesia, revised cardiac risk index[RCRI], beta-blocker usage,
33 statin usage, angiotensin-converting enzyme inhibitor[ACEI]/ Angiotensin Receptor
34 Blocker[ARB] usage, calcium channel blocker usage, aspirin usage), follow-up
35 period, detection kit of cTn, URL of cTn, detection limit of cTn, cutoff value of cTn,
36 and the different categories for postoperative cTn level.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Risk of Bias Assessment**

52
53
54 The methodological quality of the studies will be evaluated in accordance with
55 the Newcastle-Ottawa quality assessment scale (NOS)¹⁹.
56
57
58
59
60

Data synthesis

The ORs or HRs in each study will be extracted or calculated from the elevated versus non-elevated categories of postoperative cTn level for the pooled analysis. Specifically, the HR will be calculated based on the Log-rank test or the Kaplan-Meier survival curve²⁰. Nonelevated category at the lowest cTn level will be chose as the reference. The DerSimonian and Laird random-effects model will be used in the pooled analysis for the potential clinical inconsistency regardless of heterogeneity test. Univariate or multivariate meta-regression and subgroup analyses will be conducted for the comparison between elevated versus non-elevated categories of postoperative cTn level²¹. Sensitivity analyses were used to assess the robustness of our results by removing each included study at one time to obtain and evaluate the remaining overall estimates of all-cause mortality or MACE. Publication bias assessment will be performed by the Begg's and Egger's test. If one study reported multiple categories (>2 categories), we will calculate the OR by using the number of event and total in all of the elevated categories and referent one for the high vs low analysis. To conduct a dose-response meta-analysis for the potential linear or restricted cubic spline regression relationship between postoperative elevated cTn levels and all-cause mortality or MACE, studies with three or more categories will be included. If the category only provides the numerical value of elevated cTn level, we will convert this into the number of times the corresponding URL in each individual study. The average level of elevated cTn in each category will be estimated by the mean of the lower and upper levels. If the highest category had an open upper level, the mean level was estimated to be 1.2x the level of the lower levels²². P<0.05 (2-sided) was considered to be statistically significant. All statistical analyses were performed in Stata software (version 10.0, StataCorp., College Station, TX, USA) and RevMan software (version 5.0, Cochrane Collaboration, Oxford, United Kingdom).

DISCUSSION

Although there has been several meta-analyses concerning about the perioperative troponin levels and adverse clinical outcomes in adult cardiac surgery, there are obvious weakness for these works (including a large amount of retrospective studies¹⁶, only focusing on preoperative troponin levels^{14 23}, without distinguishing preoperative and postoperative troponin levels ²⁴. Moreover, no previous meta-analysis has studied the potential linear or non-linear dose-response relationship between postoperative troponin level and adverse clinical outcomes in adult cardiac surgery. In addition, several recent studies have reported the prognostic role of subclinical or tiny myocardial injury (below URL)¹⁷, which need to be paid attention for early risk stratification and improved outcomes in the future.

The strengths of this systematic review and meta-analysis include the prospective design in all the included studies, and its ability in gathering a large study population in this area. Moreover, for the first time, we will explore a potential linear or nonlinear dose-response relationship between postoperative cTn level and adverse clinical outcomes. In addition, the significance of subclinical or tiny myocardial injury below URL will firstly be focused¹⁷. The limitations, on the other hand, are also existed in our analysis. Firstly, the univariate or multivariate meta-regression and subgroup analyses are mainly based on the aggregate patient data, but not individual patient data. Other confounding factors may be underestimated. Secondly, we will focus the effect of baseline cTn level in the analysis. However, the baseline cTn level is not a regular test for patients undergoing noncardiac surgery resulting insufficient data. Thirdly, we could not rule out the potential influence of different detection kit and method for the cTn level in the included studies. Fourthly, our analysis may not be sufficient for a diagnosis of myocardial infarction for lacking additional evidence of myocardial ischemia (electrocardiography, echocardiography, coronary CT or angiography) required in the fourth UDMI.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ETHICS AND DISSEMINATION

Ethical approval is waived according to the Institutional Review Board /Independent Ethics Committee of Fuwai Hospital. This meta-analysis will be disseminated through a peer-reviewed journal for publication and conference presentations.

For peer review only

Reference

1. Puelacher C, Lurati Buse G, Seeberger D, et al. Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. *Circulation* 2018;137(12):1221-32.
2. Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. *Clin Biochem* 2011;44(12):1021-4.
3. Hietala P, Strandberg M, Kiviniemi T, et al. Usefulness of troponin T to predict short-term and long-term mortality in patients after hip fracture. *Am J Cardiol* 2014;114(2):193-7.
4. Gillies MA, Shah AS, Mullenheim J, et al. Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial. *Br J Anaesth* 2015;115(2):227-33.
5. Liem VGB, Hoeks SE, Mol K, et al. Postoperative Hypotension after Noncardiac Surgery and the Association with Myocardial Injury. *Anesthesiology* 2020;133(3):510-22.
6. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol* 2018;72(18):2231-64.
7. Sousa J, Rocha-Neves J, Oliveira-Pinto J, et al. Myocardial injury after non-cardiac surgery (MINS) in EVAR patients: a retrospective single-centre study. *J Cardiovasc Surg (Torino)* 2020. (accessed Sep 4).
8. Gualandro DM, Campos CA, Calderaro D, et al. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous. *Atherosclerosis* 2012;222(1):191-5.
9. Sheth T, Chan M, Butler C, et al. Prognostic capabilities of coronary computed tomographic angiography before non-cardiac surgery: prospective cohort study. *BMJ* 2015;350:h1907.
10. Devereaux PJ, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. *Eur Heart J* 2020;41(32):3083-91.
11. Park J, Hyeon CW, Lee SH, et al. Mildly Elevated Cardiac Troponin below the 99th-Percentile Upper Reference Limit after Noncardiac Surgery. *Korean Circ J* 2020;50(10):925-37.
12. Millán-Figueroa A, López-Navarro JM, Pérez-Díaz I, et al. Evaluation of Perioperative High-Sensitive Cardiac Troponin I as a Predictive Biomarker of Major Adverse Cardiovascular Events After Noncardiac Surgery. *Rev Invest Clin* 2020;73(3)
13. Conti D, Ballo P, Ruggiano P, et al. Very early postoperative troponin increase and clinical outcome in patients admitted to the recovery room after noncardiac surgery with suspected cardiac events. *Indian Heart J* 2020;72(3):197-9.
14. Humble CAS, Huang S, Jammer I, et al. Prognostic performance of preoperative cardiac troponin and perioperative changes in cardiac troponin for the prediction of major adverse cardiac events and mortality in noncardiac surgery: A systematic review and meta-analysis. *PLoS One* 2019;14(4):e0215094.
15. Nagele P, Rao LK, Penta M, et al. Postoperative myocardial injury after major head and neck cancer surgery. *Head Neck* 2011;33(8):1085-91.
16. Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. *Anesthesiology* 2011;114(4):796-806.
17. Cho SW. Subclinical and Tiny Myocardial Injury within Upper Reference Limit of Cardiac Troponin Should Not Be Ignored after Noncardiac Surgery. *Korean Circ J* 2020;50(10):938-9.

- 1
2
3 18. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and
4 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647.
5
6 19. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case
7 reports. *BMJ Evid Based Med* 2018;23(2):60-3.
8
9 20. Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event
10 outcomes. *Stat Med* 2002;21(22):3337-51.
11
12 21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
13 2002;21(11):1539-58.
14
15 22. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data.
16 *Epidemiology* 1993;4(3):218-28.
17
18 23. Shen JT, Xu M, Wu Y, et al. Association of pre-operative troponin levels with major adverse cardiac
19 events and mortality after noncardiac surgery: A systematic review and meta-analysis. *Eur J*
20 *Anaesthesiol* 2018;35(11):815-24.
21
22 24. Zhang LJ, Li N, Li Y, et al. Cardiac Biomarkers Predicting MACE in Patients Undergoing Noncardiac
23 Surgery: A Meta-Analysis. *Front Physiol* 2018;9:1923.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Author Contributions** CZ and TT contributed to the conception and design of the
5 study, and revision of the protocol. The manuscript of the protocol was drafted by TA.
6 TA and JG will independently search and select the eligible studies and extract the
7 data from the included studies. YT and WK will assess methodological quality and
8 the risk of bias. All the authors approved the protocol publication.
9
10
11
12
13
14
15

16 **Funding** This study was supported by the National Natural Science Foundation of
17 China (no. 81970290[Chenghui Zhou] and 81400271[Chenghui Zhou]).
18
19
20
21

22 **Competing interests** None declared.
23
24
25

26 **Patient and public involvement** Patients and/or the public were not involved in
27 the design, or conduct, or reporting or dissemination plans of this research.
28
29
30
31

32 **Patient consent for publication** Not required.
33
34
35

36 **Provenance and peer review** Not commissioned; externally peer reviewed.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Flow Chart of the Trial Searching Process.

For peer review only

Table 1 Search strategy for PubMed, EMBase, Cochrane Library, and ISI Knowledge via Web of Science Database

Database	Search items
PubMed	
No.	
# 1	((((troponin) OR (troponins)) OR (TnI)) OR (TnT)) OR (myocardial injury)
# 2	(noncardiac surgery) OR (non-cardiac surgery)
# 3	# 1 and # 2
EMBase	
# 1	troponin OR troponins OR tni OR tnt OR (myocardial AND injury)
# 2	noncardiac AND surgery OR ('non cardiac' AND surgery)
# 3	# 1 and # 2

Cochrane Library

1 troponin in All Text OR troponins in All Text OR TnI in All Text OR TnT in All Text
OR myocardial injury in All Text

2 noncardiac surgery in All Text OR non-cardiac surgery in All Text

3 # 1 and # 2

ISI Knowledge**via Web of****Science**


1 (troponin) OR TOPIC: (troponins) OR TOPIC: (TnI) OR TOPIC: (TnT) OR TOPIC:
(myocardial injury)

Timespan: All years. Databases: WOS, BIOSIS, KJD, MEDLINE, RSCI, SCIELO.

Search language=Auto

-
- 1
2
3
4
5 # 2 TOPIC: (noncardiac surgery) OR TOPIC: (non-cardiac surgery) Timespan: All years.
6 Databases: WOS, BIOSIS, KJD, MEDLINE, RSCI, SCIELO. Search language=Auto
7
8
9
10 # 3 # 1 and # 2
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

	Reporting Item	Page Number
Title		
Identification	#1a Identify the report as a protocol of a systematic review	1
Update	#1b If the protocol is for an update of a previous systematic review, identify as such	No update
Registration		
	#2 If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors		
Contact	#3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b Describe contributions of protocol authors and identify the guarantor of the review	12
Amendments		Not Amendments
	#4 If the protocol represents an amendment of a previously completed or published protocol, identify as	

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

such and list changes; otherwise, state plan for documenting important protocol amendments

Support

Sources	#5a	Indicate sources of financial or other support for the review	12
Sponsor	#5b	Provide name for the review funder and / or sponsor	12
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	12

Introduction

Rationale	#6	Describe the rationale for the review in the context of what is already known	5
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6

Methods

Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6
Study records - data management	#11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	6
Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	6
Study records - data collection process	#11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	6
Data items	#12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	6

1	Outcomes and	#13	List and define all outcomes for which data will be sought, including prioritization of main and	6,7
2				
3	prioritization		additional outcomes, with rationale	
4				
5	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this	7
6				
7	individual studies		will be done at the outcome or study level, or both; state how this information will be used in data	
8				
9			synthesis	
10				
11	Data synthesis	#15a	Describe criteria under which study data will be quantitatively synthesised	8
12				
13	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of	8
14			handling data and methods of combining data from studies, including any planned exploration of	
15				
16			consistency (such as I ² , Kendall's T)	
17				
18	Data synthesis	#15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-	8
19				
20			regression)	
21	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8
22				
23				
24				
25	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies,	8
26				
27			selective reporting within studies)	
28				
29	Confidence in	#17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8
30				
31	cumulative evidence			
32				
33				
34				
35				
36				
37	None		The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist can be completed	
38				
39	online using		https://www.goodreports.org/ , a tool made by the EQUATOR Network in collaboration with Penelope.ai	
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

BMJ Open

Dose-response Effect of Postprocedural Elevated Cardiac Troponin Level on Adverse Clinical Outcomes Following Adult Noncardiac Surgery: A Systematic Review Protocol of Prospective Studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046223.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Feb-2021
Complete List of Authors:	An, Tao; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Heart failure center Tian, Yue; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Echocardiography Guo, Jingfei; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology Kang, Wenying; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology Tian, Tao; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Zhou, Chenghui; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice, Intensive care, Epidemiology, Diagnostics
Keywords:	Adult anaesthesia < ANAESTHETICS, Adult intensive & critical care < ANAESTHETICS, Anaesthesia in cardiology < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Dose-response Effect of Postprocedural Elevated Cardiac Troponin Level on Adverse Clinical Outcomes Following Adult Noncardiac Surgery: A Systematic Review Protocol of Prospective Studies

Tao An¹, M.D, Ph.D; Yue Tian², M.D; Jingfei Guo¹, M.D; Wenyang Kang, M.D; Tao Tian^{*3}, M.D, Ph.D ; Chenghui Zhou^{*4}, M.D, Ph.D,

¹State Key Laboratory of Cardiovascular Disease, Heart Failure Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

²Department of Echocardiography, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, China

³Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing, China.

⁴Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

***Address for Correspondence:** Tao Tian and Chenghui Zhou;

No. 167 Beilishi Road, 100037 Xicheng District, Beijing, China

Tel: 86-10-88398082, Fax: 86-10-88398082

E-mail: tiantaophd@163.com (Tian T); chenghuizhou@yahoo.com (Zhou Ch) .

Word Count: 3278 words.

ABSTRACT

Introduction Myocardial injury after noncardiac surgery (MINS) has been recognized as one important complication in association with short-term and long-term morbidity and mortality. However, whether higher level of postoperative cardiac troponin (cTn) possess higher incidence of major complications remains controversial. Hence, we will conduct a comprehensive dose-response meta-analysis based on the all related prospective studies to quantitatively evaluate the association between the postoperative elevated cTn levels and short-/long-term adverse clinical outcomes following adult noncardiac surgery.

Methods We will search PubMed, EMBase, Cochrane Library, ISI Knowledge via Web of Science, China National Knowledge Infrastructure, Wanfang and VIP database (from inception until Oct, 2020) to identify all prospective cohort studies using the related keywords. The primary outcome will be all-cause mortality. The second outcomes will include cardiovascular mortality and major adverse cardiovascular event (MACE). Univariable or multivariable meta-regression and subgroup analyses will be conducted for the comparison between elevated versus non-elevated categories of postoperative cTn level. Sensitivity analyses will be used to assess the robustness of our results by removing each included study at one time to obtain and evaluate the remaining overall estimates of all-cause mortality or MACE. To conduct a dose-response meta-analysis for the potential linear or restricted cubic spline regression relationship between postoperative elevated cTn levels and all-cause mortality or MACE, studies with three or more categories will be included.

Ethics and dissemination Ethical approval is waived for the systematic review protocol according to the Institutional Review Board /Independent Ethics Committee of Fuwai Hospital. This meta-analysis will be disseminated through a peer-reviewed journal for publication and conference presentations.

Keywords: myocardial injury, noncardiac surgery, postoperative cardiac troponin,

1
2
3
4 dose-response
5

6 **PROSPERO registration number** CRD42020173175.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

1. This meta-analysis will be the first one to explore the potential linear or nonlinear dose-response relationship between postoperative cTn level and adverse clinical outcomes in adult non-cardiac surgery.
2. This meta-analysis will firstly focus on the prognostic significance of subclinical or tiny myocardial injury below URL of cTn.
3. This meta-analysis will include the largest prospective study population.
4. The baseline cTn level is not a regular test for patients undergoing noncardiac surgery.
5. This work could not rule out the potential influence of different cTn detection kits and methods.

Introduction

Myocardial injury after noncardiac surgery (MINS) has been recognized as one important complication in association with short-term and long-term morbidity and mortality¹. Some studies have showed that the incidence of MINS is common as many as 30~45% based on postoperative high sensitive cardiac troponin(cTn) level²⁻⁴. The major proposed mechanisms of MINS include imbalance of myocardial oxygen supply-demand including perioperative hypotension⁵, hypoxia⁶, anemia⁷, previous coronary artery disease(CAD)⁸, and coronary thrombosis⁹. Postoperative cTn measurement is recommended in high-risk (previous CAD, previous heart failure, previous atrial fibrillation, previous heart disease, etc) patients undergoing noncardiac surgery. According to the latest fourth Universal Definition of Myocardial Infarction (UDMI) in 2018⁶, the cutoff value for regularly diagnosing MINS is the 99th percentile upper reference limit (URL) of postoperative cTn level. However, increase in prognostic effect of cTn still requires the newly-onset ischemia-related evidence of myocardium including electrocardiogram, echocardiography, coronary computed tomography (CT), or coronary angiography⁶. However, these cardiac-specific examinations are not regularly used in patients undergoing noncardiac surgery, and may increase a large amount of cost during hospitalization.

Given the limited high-quality evidence and controversial findings from available studies concerning the long-term prognostic significance following noncardiac surgery, whether there is an optimal cutoff value for postoperative cTn level to diagnose MINS with improved prognostic significance remains unknown¹⁰⁻¹⁶. Moreover, quantitative analysis for myocardial injury below the recommended URL has not been systematically studied¹⁷. Hence, we will conduct a comprehensive dose-response meta-analysis based on the all related prospective studies to quantitatively evaluate the association between the postoperative elevated cTn levels and short-/long-term adverse clinical outcomes following noncardiac surgery.

Objectives

The purpose of this systematic review and meta-analysis is to explore the potential dose-response relationship between postoperative elevated cTn levels and adverse clinical outcomes after adult noncardiac surgery.

METHODS AND ANALYSIS

Search Strategy

We will report this meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guideline¹⁸. We will search PubMed, EMBase, Cochrane Library, and ISI Knowledge via Web of Science database (from inception until Oct, 2020), and the reference lists of the retrieved articles. The related search keywords are listed in Table 1. We will also search China National Knowledge Infrastructure, Wanfang and VIP Database (from inception until Oct, 2020) using the translated Chinese search keywords accordingly. This meta-analysis has been registered in the PROSPERO with registration ID CRD42020173175. The searching process is shown in Figure 1.

Type of Participants

We will include adult patients undergoing noncardiac surgery as study participants.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Type of Studies

We will include prospective cohort studies that have reported the associations of the postoperative cardiac troponin levels with the incidence of major adverse clinical outcomes. No language restriction will be used. For the studies unable to extract

odds ratio (OR) or hazard ratio (HR) and the corresponding 95% confidence intervals (CI) , we will perform a related systematic review in a section.

Definition of MINS

We will not set a constant value for the definition of MINS. If a precise cutoff value has been provided in each study, the definition of MINS will be accepted. Three types of cutoff value will be existed: ① detection limit below URL; ② URL; ③ a value above URL. This definition is not according to the UDMI⁶ or Standardized Endpoints in Perioperative Medicine initiative¹⁹ for the exploration of dose-response relationship.

Type of Outcomes

The primary outcome will be all-cause mortality. The second outcomes will include cardiovascular mortality and major adverse cardiovascular event (MACE). MACE is a combined endpoint including at least three of the following events: death, cardiovascular death, any cause for coronary revascularization, unstable angina, myocardial infarction, congestive heart failure, major adverse arrhythmias requiring treatment, cardiac arrest, pulmonary embolism, or stroke. The follow-up duration will be divided into three time periods: ‘short term (1-3 months)’ , ‘medium term (3~12 months)’ , and ‘long term (≥ 1 year)’ . Both primary outcome and second outcome will be included in the dose-response analysis.

Data Extraction

Data will be extracted by two independent authors (T. An and T. Yue). Discrepancies will be resolved by group discussion. The extracted data included study design (author, publication year, country, sample size, percentage of positive cTn levels), patient characteristics (mean age, male proportion, diabetes proportion, hypertension proportion, hyperlipidemia proportion, smoking proportion, CAD proportion, previous myocardial infarction, chronic heart failure, atrial fibrillation,

1
2
3
4 history of valvular heart disease, history of peripheral vascular disease, history of
5 stroke or transient ischemic accident, kidney dysfunction, history of lung disease,
6 history of liver disease, elective surgery proportion, vascular surgery proportion,
7 general anesthesia, revised cardiac risk index, beta-blocker usage, statin usage,
8 angiotensin-converting enzyme inhibitor/ Angiotensin Receptor Blocker usage,
9 calcium channel blocker usage, aspirin usage), follow-up period, detection kit of cTn,
10 URL of cTn, detection limit of cTn, cutoff value of cTn, and the different categories
11 for postoperative cTn level.
12
13
14
15
16
17
18
19
20
21

22 **Risk of Bias Assessment**

23
24 The methodological quality of the studies will be evaluated in accordance with
25 the Newcastle-Ottawa quality assessment scale (NOS)²⁰.
26
27
28
29

30 **Data synthesis**

31
32 The ORs or HRs in each study will be extracted or calculated from the elevated
33 versus non-elevated categories of postoperative cTn level for the pooled analysis.
34 Specifically, the HR will be calculated based on the Log-rank test or the
35 Kaplan-Meier survival curve²¹. Nonelevated category at the lowest cTn level will be
36 chose as the reference. The DerSimonian and Laird random-effects model will be
37 used in the pooled analysis for the potential clinical inconsistency regardless of
38 heterogeneity test. Univariable or multivariable meta-regression and subgroup
39 analyses will be conducted for the comparison between elevated versus non-elevated
40 categories of postoperative cTn level including but not limited to age, surgical types,
41 sex, and cTn types (high sensitive versus non-high sensitive, cTnI versus cTnT,
42 baseline cTn versus without baseline cTn)²². Sensitivity analyses will be used to
43 assess the robustness of our results by removing each included study at one time to
44 obtain and evaluate the remaining overall estimates of all-cause mortality or MACE.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Publication bias assessment will be performed by the Begg's and Egger's test. If one

1
2
3
4 study reported multiple categories (>2 categories), we will calculate the OR by using
5 the number of event and total in all of the elevated categories and referent one for the
6 high vs low analysis. To conduct a dose-response meta-analysis for the potential
7 linear or restricted cubic spline regression relationship between postoperative elevated
8 cTn levels and all-cause mortality or MACE, studies with three or more categories
9 will be included. If the category only provides the numerical value of elevated cTn
10 level, we will convert this into the number of times the corresponding URL in each
11 individual study. The average level of elevated cTn in each category will be estimated
12 by the mean of the lower and upper levels. If the highest category had an open upper
13 level, the mean level will be estimated to be 1.2x the level of the lower levels²³.
14 P<0.05 (2-sided) will be considered to be statistically significant. All statistical
15 analyses will be performed in Stata software (version 10.0, StataCorp., College
16 Station, TX, USA) and RevMan software (version 5.0, Cochrane Collaboration,
17 Oxford, United Kingdom).

34 **DISCUSSION**

35
36
37 Although there have been several meta-analyses concerning about the prognostic
38 effect of pre- and/or post-operative troponin levels in adult noncardiac surgery, there
39 are obvious pitfalls for these works (including a large amount of retrospective
40 studies¹⁶, only focusing on preoperative troponin levels^{14 24}, without distinguishing
41 preoperative and postoperative troponin levels²⁵). Moreover, none of them have
42 studied the potential linear or non-linear dose-response relationship between
43 postoperative troponin level and adverse clinical outcomes in adult noncardiac
44 surgery. In addition, the prognostic role of subclinical or tiny myocardial injury
45 (below URL)¹⁷ has been largely ignored for early risk stratification and improved
46 outcomes in adult noncardiac surgery.

47
48
49 The strengths of this systematic review and meta-analysis include the prospective
50 design in all the included studies, and its ability in gathering a large study population

1
2
3
4 in this area. Moreover, for the first time, we will explore a potential linear or
5
6 nonlinear dose-response relationship between postoperative cTn level and adverse
7
8 clinical outcomes. In addition, the prognostic significance of subclinical or tiny
9
10 myocardial injury below URL will firstly be focused¹⁷. The limitations, on the other
11
12 hand, are also existed in our analysis. Firstly, the univariable or multivariable
13
14 meta-regression and subgroup analyses are mainly based on the aggregate patient
15
16 data, but not individual patient data. Other confounding factors may be
17
18 underestimated. Secondly, we will focus the effect of baseline cTn level in the
19
20 analysis. However, the baseline cTn level is not a regular test for patients undergoing
21
22 noncardiac surgery. Thirdly, we could not rule out the potential influence of different
23
24 detection kits and methods for the cTn level in the included studies. Fourthly, our
25
26 analysis may not be sufficient for a diagnosis of myocardial infarction for lacking
27
28 additional evidence of myocardial ischemia (electrocardiography, echocardiography,
29
30 coronary CT or angiography) required in the fourth UDMI. Lastly, elevated troponin
31
32 has been observed in non-cardiac situations such as pulmonary embolism or renal
33
34 dysfunction, and thus might not be a marker of only direct cardiac problems.
35
36
37
38

39 **ETHICS AND DISSEMINATION**

40
41 Ethical approval is waived according to the Institutional Review Board /Independent
42
43 Ethics Committee of Fuwai Hospital. This meta-analysis will be disseminated through
44
45 a peer-reviewed journal for publication and conference presentations.
46
47

48 **Author Contributions** CZ and TT contributed to the conception and design of the
49
50 study, and revision of the protocol. The manuscript of the protocol was drafted by TA.
51
52 TA and JG will independently search and select the eligible studies and extract the
53
54 data from the included studies. YT and WK will assess methodological quality and
55
56 the risk of bias. All the authors approved the protocol publication.
57

58 **Competing interests** None declared.
59

60 **Funding** This study was supported by the National Natural Science Foundation of

China (no. 81970290), and the Clinical Research Foundation of Fuwai Hospital (no. 2016-ZX033).

Reference

1. C. Puelacher, Lurati Buse G., Seeberger D., et al. Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. *Circulation* 2018;137(12):1221-32.
2. P. A. Kavsak, Walsh M., Srinathan S., et al. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. *Clin Biochem* 2011;44(12):1021-4.
3. P. Hietala, Strandberg M., Kiviniemi T., et al. Usefulness of troponin T to predict short-term and long-term mortality in patients after hip fracture. *Am J Cardiol* 2014;114(2):193-7.
4. M. A. Gillies, Shah A. S., Mullenheim J., et al. Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial. *Br J Anaesth* 2015;115(2):227-33.
5. V. G. B. Liem, Hoeks S. E., Mol Khjm, et al. Postoperative Hypotension after Noncardiac Surgery and the Association with Myocardial Injury. *Anesthesiology* 2020;133(3):510-22.
6. K. Thygesen, Alpert J. S., Jaffe A. S., et al. Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol* 2018;72(18):2231-64.
7. J. Sousa, Rocha-Neves J., Oliveira-Pinto J., et al. Myocardial injury after non-cardiac surgery (MINS) in EVAR patients: a retrospective single-centre study. *J Cardiovasc Surg (Torino)* 2020. (accessed Sep 4).
8. D. M. Gualandro, Campos C. A., Calderaro D., et al. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous. *Atherosclerosis* 2012;222(1):191-5.
9. T. Sheth, Chan M., Butler C., et al. Prognostic capabilities of coronary computed tomographic angiography before non-cardiac surgery: prospective cohort study. *BMJ* 2015;350:h1907.
10. P. J. Devereaux, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. *Eur Heart J* 2020;41(32):3083-91.
11. J. Park, Hyeon C. W., Lee S. H., et al. Mildly Elevated Cardiac Troponin below the 99th-Percentile Upper Reference Limit after Noncardiac Surgery. *Korean Circ J* 2020;50(10):925-37.
12. A. Millán-Figueroa, López-Navarro J. M., Pérez-Díaz I., et al. Evaluation of Perioperative High-Sensitive Cardiac Troponin I as a Predictive Biomarker of Major Adverse Cardiovascular Events After Noncardiac Surgery. *Rev Invest Clin* 2020;73(3)
13. D. Conti, Ballo P., Ruggiano P., et al. Very early postoperative troponin increase and clinical outcome in patients admitted to the recovery room after noncardiac surgery with suspected cardiac events. *Indian Heart J* 2020;72(3):197-9.
14. C. A. S. Humble, Huang S., Jammer I., et al. Prognostic performance of preoperative cardiac troponin and perioperative changes in cardiac troponin for the prediction of major adverse cardiac events and mortality in noncardiac surgery: A systematic review and meta-analysis. *PLoS One* 2019;14(4):e0215094.
15. P. Nagele, Rao L. K., Penta M., et al. Postoperative myocardial injury after major head and neck cancer surgery. *Head Neck* 2011;33(8):1085-91.
16. M. Levy, Heels-Ansdell D., Hiralal R., et al. Prognostic value of troponin and creatine kinase muscle

- 1
2
3 and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis.
4 *Anesthesiology* 2011;114(4):796-806.
- 5
6 17. S. W. Cho. Subclinical and Tiny Myocardial Injury within Upper Reference Limit of Cardiac
7 Troponin Should Not Be Ignored after Noncardiac Surgery. *Korean Circ J* 2020;50(10):938-9.
- 8
9 18. L. Shamseer, Moher D., Clarke M., et al. Preferred reporting items for systematic review and
10 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647.
- 11
12 19. W. S. Beattie, Lalu M., Boccock M., et al. Systematic review and consensus definitions for the
13 Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes. *Br J*
14 *Anaesth* 2021;126(1):56-66.
- 15
16 20. M. H. Murad, Sultan S., Haffar S., et al. Methodological quality and synthesis of case series and
17 case reports. *BMJ Evid Based Med* 2018;23(2):60-3.
- 18
19 21. P. R. Williamson, Smith C. T., Hutton J. L., et al. Aggregate data meta-analysis with time-to-event
20 outcomes. *Stat Med* 2002;21(22):3337-51.
- 21
22 22. J. P. Higgins, Thompson S. G. Quantifying heterogeneity in a meta-analysis. *Stat Med*
23 2002;21(11):1539-58.
- 24
25 23. J. A. Berlin, Longnecker M. P., Greenland S. Meta-analysis of epidemiologic dose-response data.
26 *Epidemiology* 1993;4(3):218-28.
- 27
28 24. J. T. Shen, Xu M., Wu Y., et al. Association of pre-operative troponin levels with major adverse
29 cardiac events and mortality after noncardiac surgery: A systematic review and meta-analysis. *Eur J*
30 *Anaesthesiol* 2018;35(11):815-24.
- 31
32 25. L. J. Zhang, Li N., Li Y., et al. Cardiac Biomarkers Predicting MACE in Patients Undergoing
33 Noncardiac Surgery: A Meta-Analysis. *Front Physiol* 2018;9:1923.
- 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Patient consent for publication** Not required.

52
53
54 **Provenance and peer review** Not commissioned; externally peer reviewed.

Figure Legends

Figure 1. Flow Chart of the Trial Searching Process.

For peer review only

Table 1 Search strategy for PubMed, EMBase, Cochrane Library, ISI Knowledge via Web of Science, China National Knowledge Infrastructure, Wanfang and VIP Database

Database	Search items
PubMed	
No.	
# 1	((((troponin) OR (troponins)) OR (TnI)) OR (TnT)) OR (myocardial injury)
# 2	(noncardiac surgery) OR (non-cardiac surgery)
# 3	# 1 and # 2
EMBase	
# 1	troponin OR troponins OR tni OR tnt OR (myocardial AND injury)
# 2	noncardiac AND surgery OR ('non cardiac' AND surgery)
# 3	# 1 and # 2
Cochrane Library	

1 troponin in All Text OR troponins in All Text OR TnI in All Text OR TnT in All Text
OR myocardial injury in All Text

2 noncardiac surgery in All Text OR non-cardiac surgery in All Text

3 # 1 and # 2

**ISI Knowledge
via Web of
Science**

1 (troponin) OR TOPIC: (troponins) OR TOPIC: (TnI) OR TOPIC: (TnT) OR TOPIC:
(myocardial injury)

Timespan: All years. Databases: WOS, BIOSIS, KJD, MEDLINE, RSCI, SCIELO.

Search language=Auto

2 TOPIC: (noncardiac surgery) OR TOPIC: (non-cardiac surgery) Timespan: All years.

Databases: WOS, BIOSIS, KJD, MEDLINE, RSCI, SCIELO. Search language=Auto

3 # 1 and # 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow Chart of the Trial Searching Process

90x90mm (300 x 300 DPI)

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

	Reporting Item	Page Number
	Title	
Identification	#1a Identify the report as a protocol of a systematic review	1
Update	#1b If the protocol is for an update of a previous systematic review, identify as such	No update
Registration		
	#2 If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors		
Contact	#3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments		Not Amendments
	#4 If the protocol represents an amendment of a previously completed or published protocol, identify as	

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

such and list changes; otherwise, state plan for documenting important protocol amendments

Support

Sources	#5a	Indicate sources of financial or other support for the review	10
Sponsor	#5b	Provide name for the review funder and / or sponsor	10
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10

Introduction

Rationale	#6	Describe the rationale for the review in the context of what is already known	5
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6

Methods

Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
Information sources	#9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	#10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6
Study records - data management	#11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	6
Study records - selection process	#11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Study records - data collection process	#11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7
Data items	#12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7

1	Outcomes and	#13	List and define all outcomes for which data will be sought, including prioritization of main and	7
2				
3	prioritization		additional outcomes, with rationale	
4				
5	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this	8
6				
7	individual studies		will be done at the outcome or study level, or both; state how this information will be used in data	
8				
9			synthesis	
10				
11	Data synthesis	#15a	Describe criteria under which study data will be quantitatively synthesised	8,9
12				
13	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of	8,9
14			handling data and methods of combining data from studies, including any planned exploration of	
15				
16			consistency (such as I ² , Kendall's T)	
17				
18	Data synthesis	#15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-	8,9
19			regression)	
20				
21	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8,9
22				
23	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8,9
24				
25	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies,	8,9
26			selective reporting within studies)	
27				
28	Confidence in	#17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8,9
29				
30	cumulative evidence			
31				
32				
33	None		The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist can be completed	
34				
35	online using		https://www.goodreports.org/ , a tool made by the EQUATOR Network in collaboration with Penelope.ai	
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

BMJ Open

Dose-response Effect of Postprocedural Elevated Cardiac Troponin Level on Adverse Clinical Outcomes Following Adult Noncardiac Surgery: A Systematic Review Protocol of Prospective Studies

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046223.R2
Article Type:	Protocol
Date Submitted by the Author:	29-May-2021
Complete List of Authors:	An, Tao; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Heart failure center Tian, Yue; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Echocardiography Guo, Jingfei; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology Kang, Wenying; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology Tian, Tao; Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital, Zhou, Chenghui; Fuwai Hospital State Key Laboratory of Cardiovascular Disease, Anesthesiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice, Intensive care, Epidemiology, Diagnostics
Keywords:	Adult anaesthesia < ANAESTHETICS, Adult intensive & critical care < ANAESTHETICS, Anaesthesia in cardiology < ANAESTHETICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Dose-response Effect of Postprocedural Elevated Cardiac Troponin Level on Adverse Clinical Outcomes Following Adult Noncardiac Surgery: A Systematic Review Protocol of Prospective Studies

Tao An¹, M.D, Ph.D; Yue Tian², M.D; Jingfei Guo¹, M.D; Wenyang Kang, M.D; Tao Tian^{*3}, M.D, Ph.D ; Chenghui Zhou^{*4}, M.D, Ph.D,

¹State Key Laboratory of Cardiovascular Disease, Heart Failure Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

²Department of Echocardiography, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, China

³Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing, China.

⁴Department of Anesthesiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

***Address for Correspondence:** Tao Tian and Chenghui Zhou;

No. 167 Beilishi Road, 100037 Xicheng District, Beijing, China

Tel: 86-10-88398082, Fax: 86-10-88398082

E-mail: tiantaophd@163.com (Tian T); chenghuizhou@yahoo.com (Zhou Ch) .

Word Count: 3387 words.

ABSTRACT

Introduction Myocardial injury after noncardiac surgery (MINS) has been recognized as an important complication associated with short-term and long-term morbidity and mortality. However, whether a higher level of postoperative cardiac troponin (cTn) is associated with a higher incidence of major complications remains controversial. Hence, we will conduct a comprehensive dose-response meta-analysis based on all relevant prospective studies to quantitatively evaluate the association between elevated postoperative cTn levels and short-/long-term adverse clinical outcomes following adult noncardiac surgery.

Methods We will search the PubMed, EMBase, Cochrane Library, ISI Knowledge via Web of Science, China National Knowledge Infrastructure, Wanfang and VIP databases (from inception until October 2020) to identify all prospective cohort studies using the relevant keywords. The primary outcome will be all-cause mortality. The second outcomes will include cardiovascular mortality and major adverse cardiovascular events (MACEs). Univariable or multivariable meta-regression and subgroup analyses will be conducted for the comparison between elevated versus nonelevated categories of postoperative cTn levels. Sensitivity analyses will be used to assess the robustness of our results by removing each included study at one time to obtain and evaluate the remaining overall estimates of all-cause mortality or MACE. To conduct a dose-response meta-analysis for the potential linear or restricted cubic spline regression relationship between postoperative elevated cTn levels and all-cause mortality or MACE, studies with three or more categories will be included.

Ethics and dissemination Ethical approval is waived for the systematic review protocol according to the Institutional Review Board/Independent Ethics Committee of Fuwai Hospital. This meta-analysis will be disseminated through a peer-reviewed journal for publication and conference presentations.

Keywords: myocardial injury, noncardiac surgery, postoperative cardiac troponin, dose-response

1
2
3
4 **PROSPERO registration number CRD42020173175.**
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- 1
2
3
4 1. The potential linear or nonlinear dose-response relationship between postoperative
5
6
7 cTn levels and adverse clinical outcomes in adult noncardiac surgery will be explored.
8
- 9
10 2. The prognostic significance of subclinical or tiny myocardial injury below the URL
11
12 of cTn will be focused.
13
- 14
15 3. This meta-analysis will pool the data from a number of studies to form the largest
16
17 prospective dataset to date.
18
- 19
20 4. The baseline cTn level is not a routine test for patients undergoing noncardiac
21
22 surgery.
23
- 24
25 5. This work cannot rule out the potential influence of different cTn detection kits and
26
27 methods used in the included studies.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Myocardial injury after noncardiac surgery (MINS) has been recognized as an important complication associated with short-term and long-term morbidity and mortality¹. Some studies have shown that the incidence of MINS is as high as 30~45% based on postoperative high-sensitive cardiac troponin (cTn) levels²⁻⁴. The major proposed mechanisms of MINS include an imbalance in myocardial oxygen supply and demand due to perioperative hypotension⁵, hypoxia⁶, anaemia⁷, previous coronary artery disease (CAD)⁸, and coronary thrombosis⁹. Postoperative cTn measurement is recommended for high-risk (previous CAD, previous heart failure, previous atrial fibrillation, previous heart disease, etc) patients undergoing noncardiac surgery. According to the fourth Universal Definition of Myocardial Infarction (UDMI) published in 2018⁶, the cut-off value for the diagnosis of MINS is the 99th percentile upper reference limit (URL) of the postoperative cTn level. However, an increase in the prognostic effect of cTn levels still requires the new-onset ischemia-related evidence in the myocardium including that from electrocardiogram, echocardiography, coronary computed tomography (CT), or coronary angiography⁶. However, these cardiac-specific examinations are not regularly used in patients undergoing noncardiac surgery, and may increase the cost of hospitalization.

Given the limited high-quality evidence available and the controversial findings revealed by available studies concerning the long-term prognostic significance of cTn levels following noncardiac surgery, whether there is an optimal cut-off value for postoperative cTn level to diagnose MINS with improved prognostic significance remains unknown¹⁰⁻¹⁶. Moreover, quantitative analysis for myocardial injury below the recommended URL has not been systematically studied¹⁷. Hence, we will conduct a comprehensive dose-response meta-analysis based on all relevant prospective studies to quantitatively evaluate the association between elevated postoperative cTn levels and short-/long-term adverse clinical outcomes following noncardiac surgery.

Objectives

The purpose of this systematic review and meta-analysis is to explore the potential dose-response relationship between postoperative elevated cTn levels and adverse clinical outcomes after adult noncardiac surgery.

METHODS AND ANALYSIS

Search Strategy

We will conduct this meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines¹⁸. We will search the PubMed, EMBase, Cochrane Library, and ISI Knowledge via the Web of Science databases (from inception until October 2020), and the reference lists of the retrieved articles. The related search keywords are listed in Table 1. We will also search the China National Knowledge Infrastructure, Wanfang and VIP Databases (from inception until October 2020) using same search keywords translated into Chinese. This meta-analysis has been registered in PROSPERO with the registration ID CRD42020173175. The proposed search process is shown in Figure 1.

Type of Participants

We will include adult patients undergoing noncardiac surgery as the study participants.

Patient and public involvement

Patients and/or the public are not involved in the design, or conduct, or reporting or dissemination plans of this research.

Type of Studies

We will include prospective cohort studies that have reported the associations between postoperative cardiac troponin levels and the incidence of major adverse

1
2
3
4 clinical outcomes. No language restriction will be used.

5 6 **Definition of MINS**

7
8 The definition of MINS with a precise cut-off value in each study will be
9
10 accepted. The following three types of cut-off value will exist: ① detection limit
11 below the URL; ② detection at the URL; ③ detection above the URL. This
12 definition based only on biomarkers of myocardial injury is not based on the UDMI⁶
13 or Standardized Endpoints in Perioperative Medicine initiative¹⁹ due to the lack of
14 availability of additional information such as electrocardiography, echocardiography,
15 coronary CT or angiography data .
16
17
18
19
20
21
22
23

24 **Type of Outcomes**

25
26 The primary outcome will be all-cause mortality. The secondary outcomes will
27 include cardiovascular mortality and major adverse cardiovascular events (MACEs).
28 MACEs constitute a combined endpoint including at least three of the following
29 events: death, cardiovascular death, coronary revascularization of any cause, unstable
30 angina, myocardial infarction, congestive heart failure, major adverse arrhythmias
31 requiring treatment, cardiac arrest, pulmonary embolism, or stroke. The follow-up
32 duration will be divided into the following three time periods: ‘short term (1-3
33 months)’ , ‘medium term (3~12 months)’ , and ‘long term (≥ 1 year)’ . Both
34 the primary outcome and secondary outcomes will be included in the dose-response
35 analysis.
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Data Extraction**

51 The data will be extracted by two independent authors (T. An and T. Yue).
52 Discrepancies will be resolved by group discussion. The extracted data will include
53 study design (author, publication year, country, sample size, percentage of positive
54 cTn levels), patient characteristics (mean age, male proportion, diabetes proportion,
55 hypertension proportion, hyperlipidemia proportion, smoking proportion, CAD
56
57
58
59
60

1
2
3
4 proportion, previous myocardial infarction, chronic heart failure, atrial fibrillation,
5
6 history of valvular heart disease, history of peripheral vascular disease, history of
7
8 stroke or transient ischemic accident, kidney dysfunction, history of lung disease,
9
10 history of liver disease, elective surgery proportion, vascular surgery proportion,
11
12 general anesthesia, revised cardiac risk index, beta-blocker usage, statin usage,
13
14 angiotensin-converting enzyme inhibitor/angiotensin receptor blocker usage, calcium
15
16 channel blocker usage, aspirin usage), follow-up period, kit used to detect cTn, the
17
18 URL of cTn, the detection limit of cTn, cut-off value of cTn, and the different
19
20 categories of postoperative cTn levels.
21
22
23

24 **Risk of Bias Assessment**

25
26 The methodological quality of the studies will be evaluated in accordance with
27
28 the Newcastle-Ottawa quality assessment scale (NOS)²⁰.
29
30
31

32 **Data synthesis**

33
34 The ORs or HRs in each study will be extracted or calculated from patients
35
36 categorized as having elevated versus nonelevated postoperative cTn levels for the
37
38 pooled analysis. Specifically, the HR will be calculated based on the log-rank test or
39
40 the Kaplan-Meier survival curve²¹. Patients in the nonelevated cTn level category with
41
42 the lowest cTn levels will be chosen as the reference points. The DerSimonian and
43
44 Laird random-effects model will be used in the pooled analysis for potential clinical
45
46 inconsistency regardless of the heterogeneity test result. Univariable or multivariable
47
48 meta-regression and subgroup analyses will be conducted for the comparison between
49
50 patients with elevated versus nonelevated postoperative cTn levels to assess the
51
52 impact of multiple potential influential factors such as surgical types, patient
53
54 characteristics, and cTn types (high sensitive versus non-high sensitive, cTnI versus
55
56 cTnT, baseline cTn versus without baseline cTn)²². Sensitivity analyses will be used
57
58 to assess the robustness of our results by removing each included study at one time to
59
60

1
2
3
4 obtain and evaluate the remaining overall estimates of all-cause mortality or MACEs.
5
6 Publication bias assessment will be performed by the Begg's and Egger's tests. If one
7
8 study reported multiple categories (>2 categories), we will calculate the OR by using
9
10 the number of events and the total in all of the elevated categories and reference one
11
12 for the high vs low analysis. To conduct a dose-response meta-analysis for the
13
14 potential linear or restricted cubic spline regression relationship between
15
16 postoperative elevated cTn levels and all-cause mortality or MACEs, studies with
17
18 three or more categories will be included. If only the numerical value of the elevated
19
20 cTn levels is provided, we will convert this into the number of times the
21
22 corresponding URL in each individual study. The average level of elevated cTn in
23
24 each category will be estimated by determining the mean of the lower and upper
25
26 levels. If the highest category has an open upper level, the mean level will be
27
28 estimated to be 1.2x the level of the lower levels²³. P<0.05 (2-sided) will be
29
30 considered statistically significant. All statistical analyses will be performed in Stata
31
32 software (version 10.0, StataCorp., College Station, TX, USA) and RevMan software
33
34 (version 5.0, Cochrane Collaboration, Oxford, United Kingdom).
35
36
37
38

39 DISCUSSION

40
41 Although there have been several meta-analyses concerning the prognostic effect
42
43 of pre- and/or postoperative troponin levels in adult noncardiac surgery, there are
44
45 obvious pitfalls in these studies (including a large number of retrospective studies¹⁶,
46
47 and studies focused only on preoperative troponin levels^{14 24} or, did not distinguish
48
49 between preoperative and postoperative troponin levels²⁵). Moreover, the potential
50
51 linear or nonlinear dose-response relationship between postoperative troponin level
52
53 and adverse clinical outcomes in adult noncardiac surgery has not been studied. In
54
55 addition, the prognostic role of subclinical or tiny myocardial injury (below the
56
57 URL)¹⁷ has been largely ignored for early risk stratification and prediction of
58
59 improved outcomes in adult noncardiac surgery.
60

1
2
3
4 The strengths of this systematic review and meta-analysis include the prospective
5 design of all the included studies, and its ability to gather a large relevant study
6 population. Moreover, for the first time, we will explore the potential linear or
7 nonlinear dose-response relationship between postoperative cTn levels and adverse
8 clinical outcomes. In addition, we will focus on the prognostic significance of
9 subclinical or tiny myocardial injury below the URL for the first time¹⁷. The
10 limitations, on the other hand, also exist in our analysis. First, the univariable or
11 multivariable meta-regression and subgroup analyses are mainly based on aggregate
12 patient data, not individual patient data. Other confounding factors may be
13 underestimated. Second, we will focus on the effect of baseline cTn level in the
14 analysis. However, the baseline cTn level is not a routine test for patients undergoing
15 noncardiac surgery. Third, we cannot rule out the potential influence of different
16 detection kits and methods used to measure the cTn levels in the included studies.
17 Fourth, our analysis may not be sufficient for a diagnosis of myocardial infarction due
18 to the lack of additional available evidence for myocardial ischemia
19 (electrocardiography, echocardiography, coronary CT or angiography) required in the
20 fourth UDMI. Last, elevated troponin has been observed in noncardiac situations such
21 as pulmonary embolism or renal dysfunction and thus might not solely be a direct
22 marker of cardiac problems.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **ETHICS AND DISSEMINATION**

46
47 Ethical approval is waived according to the Institutional Review Board /Independent
48 Ethics Committee of Fuwai Hospital. This meta-analysis will be disseminated through
49 a peer-reviewed journal for publication and conference presentations.
50
51

52
53 **Author Contributions** CZ and TT contributed to the conception and design of the
54 study, and revision of the protocol. The manuscript of the protocol was drafted by TA.
55 TA and JG will independently search and select the eligible studies and extract the
56 data from the included studies. YT and WK will assess methodological quality and
57
58
59
60

1
2
3
4 the risk of bias. All the authors approved the protocol publication.

5
6 **Competing interests** None declared.

7
8 **Funding** This study was supported by the National Natural Science Foundation of
9
10 China (no. 81970290), and the Clinical Research Foundation of Fuwai Hospital (no.
11
12 2016-ZX033).

13 14 **Reference**

- 15 1. C. Puelacher, Lurati Buse G., Seeberger D., et al. Perioperative Myocardial Injury After Noncardiac
16 Surgery: Incidence, Mortality, and Characterization. *Circulation* 2018;137(12):1221-32.
- 17 2. P. A. Kavsak, Walsh M., Srinathan S., et al. High sensitivity troponin T concentrations in patients
18 undergoing noncardiac surgery: a prospective cohort study. *Clin Biochem* 2011;44(12):1021-4.
- 19 3. P. Hietala, Strandberg M., Kiviniemi T., et al. Usefulness of troponin T to predict short-term and
20 long-term mortality in patients after hip fracture. *Am J Cardiol* 2014;114(2):193-7.
- 21 4. M. A. Gillies, Shah A. S., Mullenheim J., et al. Perioperative myocardial injury in patients receiving
22 cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial. *Br J Anaesth*
23 2015;115(2):227-33.
- 24 5. V. G. B. Liem, Hoeks S. E., Mol Khjm, et al. Postoperative Hypotension after Noncardiac Surgery and
25 the Association with Myocardial Injury. *Anesthesiology* 2020;133(3):510-22.
- 26 6. K. Thygesen, Alpert J. S., Jaffe A. S., et al. Fourth Universal Definition of Myocardial Infarction
27 (2018). *J Am Coll Cardiol* 2018;72(18):2231-64.
- 28 7. J. Sousa, Rocha-Neves J., Oliveira-Pinto J., et al. Myocardial injury after non-cardiac surgery (MINS)
29 in EVAR patients: a retrospective single-centre study. *J Cardiovasc Surg (Torino)* 2020. (accessed Sep
30 4).
- 31 8. D. M. Gualandro, Campos C. A., Calderaro D., et al. Coronary plaque rupture in patients with
32 myocardial infarction after noncardiac surgery: frequent and dangerous. *Atherosclerosis*
33 2012;222(1):191-5.
- 34 9. T. Sheth, Chan M., Butler C., et al. Prognostic capabilities of coronary computed tomographic
35 angiography before non-cardiac surgery: prospective cohort study. *BMJ* 2015;350:h1907.
- 36 10. P. J. Devereaux, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and
37 management. *Eur Heart J* 2020;41(32):3083-91.
- 38 11. J. Park, Hyeon C. W., Lee S. H., et al. Mildly Elevated Cardiac Troponin below the 99th-Percentile
39 Upper Reference Limit after Noncardiac Surgery. *Korean Circ J* 2020;50(10):925-37.
- 40 12. A. Millán-Figueroa, López-Navarro J. M., Pérez-Díaz I., et al. Evaluation of Perioperative
41 High-Sensitive Cardiac Troponin I as a Predictive Biomarker of Major Adverse Cardiovascular Events
42 After Noncardiac Surgery. *Rev Invest Clin* 2020;73(3)
- 43 13. D. Conti, Ballo P., Ruggiano P., et al. Very early postoperative troponin increase and clinical
44 outcome in patients admitted to the recovery room after noncardiac surgery with suspected cardiac
45 events. *Indian Heart J* 2020;72(3):197-9.
- 46 14. C. A. S. Humble, Huang S., Jammer I., et al. Prognostic performance of preoperative cardiac
47 troponin and perioperative changes in cardiac troponin for the prediction of major adverse cardiac
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 events and mortality in noncardiac surgery: A systematic review and meta-analysis. *PLoS One*
4 2019;14(4):e0215094.
5
6 15. P. Nagele, Rao L. K., Penta M., et al. Postoperative myocardial injury after major head and neck
7 cancer surgery. *Head Neck* 2011;33(8):1085-91.
8
9 16. M. Levy, Heels-Ansdell D., Hiralal R., et al. Prognostic value of troponin and creatine kinase muscle
10 and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis.
11 *Anesthesiology* 2011;114(4):796-806.
12
13 17. S. W. Cho. Subclinical and Tiny Myocardial Injury within Upper Reference Limit of Cardiac
14 Troponin Should Not Be Ignored after Noncardiac Surgery. *Korean Circ J* 2020;50(10):938-9.
15
16 18. L. Shamseer, Moher D., Clarke M., et al. Preferred reporting items for systematic review and
17 meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;350:g7647.
18
19 19. W. S. Beattie, Lalu M., Bockock M., et al. Systematic review and consensus definitions for the
20 Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes. *Br J*
21 *Anaesth* 2021;126(1):56-66.
22
23 20. M. H. Murad, Sultan S., Haffar S., et al. Methodological quality and synthesis of case series and
24 case reports. *BMJ Evid Based Med* 2018;23(2):60-3.
25
26 21. P. R. Williamson, Smith C. T., Hutton J. L., et al. Aggregate data meta-analysis with time-to-event
27 outcomes. *Stat Med* 2002;21(22):3337-51.
28
29 22. J. P. Higgins, Thompson S. G. Quantifying heterogeneity in a meta-analysis. *Stat Med*
30 2002;21(11):1539-58.
31
32 23. J. A. Berlin, Longnecker M. P., Greenland S. Meta-analysis of epidemiologic dose-response data.
33 *Epidemiology* 1993;4(3):218-28.
34
35 24. J. T. Shen, Xu M., Wu Y., et al. Association of pre-operative troponin levels with major adverse
36 cardiac events and mortality after noncardiac surgery: A systematic review and meta-analysis. *Eur J*
37 *Anaesthesiol* 2018;35(11):815-24.
38
39 25. L. J. Zhang, Li N., Li Y., et al. Cardiac Biomarkers Predicting MACE in Patients Undergoing
40 Noncardiac Surgery: A Meta-Analysis. *Front Physiol* 2018;9:1923.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **Patient consent for publication** Not required.
7
8
9

10 **Provenance and peer review** Not commissioned; externally peer reviewed.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Flow Chart of the Trial Searching Process.

For peer review only

Table 1 Search strategy for PubMed, EMBase, Cochrane Library, ISI Knowledge via Web of Science, China National Knowledge Infrastructure, Wanfang and VIP Database

Database	Search items
PubMed	
No.	
# 1	((((troponin) OR (troponins)) OR (TnI)) OR (TnT)) OR (myocardial injury)
# 2	(noncardiac surgery) OR (non-cardiac surgery)
# 3	# 1 and # 2
EMBase	
# 1	troponin OR troponins OR tni OR tnt OR (myocardial AND injury)
# 2	noncardiac AND surgery OR ('non cardiac' AND surgery)
# 3	# 1 and # 2
Cochrane Library	

- # 1 troponin in All Text OR troponins in All Text OR TnI in All Text OR TnT in All Text
OR myocardial injury in All Text
- # 2 noncardiac surgery in All Text OR non-cardiac surgery in All Text
- # 3 # 1 and # 2
- ISI Knowledge
via Web of
Science**
- # 1 (troponin) OR TOPIC: (troponins) OR TOPIC: (TnI) OR TOPIC: (TnT) OR TOPIC:
(myocardial injury)
Timespan: All years. Databases: WOS, BIOSIS, KJD, MEDLINE, RSCI, SCIELO.
Search language=Auto
- # 2 TOPIC: (noncardiac surgery) OR TOPIC: (non-cardiac surgery) Timespan: All years.
Databases: WOS, BIOSIS, KJD, MEDLINE, RSCI, SCIELO. Search language=Auto
- # 3 # 1 and # 2




Figure 1. Flow Chart of the Trial Searching Process.

127x116mm (600 x 600 DPI)

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Preorting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1.

		Reporting Item	Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	No update
Registration			
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors			
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	10

Amendments		Not Amendments
Support		
Sources	#4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	
Sponsor	#5a Indicate sources of financial or other support for the review	11
Sponsor	#5b Provide name for the review funder and / or sponsor	11
Role of sponsor or funder	#5c Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	11
Introduction		
Rationale	#6 Describe the rationale for the review in the context of what is already known	5
Objectives	#7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	6
Methods		
Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6
Information sources	#9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	#10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	6
Study records - data management	#11a Describe the mechanism(s) that will be used to manage records and data throughout the review	6

1	Study records -	#11b	State the process that will be used for selecting studies	7
2	selection process		(such as two independent reviewers) through each	
3			phase of the review (that is, screening, eligibility and	
4			inclusion in meta-analysis)	
5				
6				
7				
8	Study records -	#11c	Describe planned method of extracting data from reports	8
9	data collection		(such as piloting forms, done independently, in	
10	process		duplicate), any processes for obtaining and confirming	
11			data from investigators	
12				
13				
14	Data items	#12	List and define all variables for which data will be sought	8
15			(such as PICO items, funding sources), any pre-planned	
16			data assumptions and simplifications	
17				
18				
19				
20	Outcomes and	#13	List and define all outcomes for which data will be	7
21	prioritization		sought, including prioritization of main and additional	
22			outcomes, with rationale	
23				
24				
25	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias	8
26	individual studies		of individual studies, including whether this will be done	
27			at the outcome or study level, or both; state how this	
28			information will be used in data synthesis	
29				
30				
31				
32	Data synthesis	#15a	Describe criteria under which study data will be	8,9
33			quantitatively synthesised	
34				
35				
36	Data synthesis	#15b	If data are appropriate for quantitative synthesis,	8,9
37			describe planned summary measures, methods of	
38			handling data and methods of combining data from	
39			studies, including any planned exploration of consistency	
40			(such as I ² , Kendall's τ)	
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	8,9
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the	8,9
49			type of summary planned	
50				
51				
52	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such	8,9
53			as publication bias across studies, selective reporting	
54			within studies)	
55				
56				
57	Confidence in	#17	Describe how the strength of the body of evidence will be	8,9
58	cumulative		assessed (such as GRADE)	
59				
60				

evidence

None The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only